# Savara Inc: overview SVRA · Nasdaq · CIK 1160308 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/svra.md) · [Financials](/companies/svra/financials.md) · [Filings](/companies/svra/filings.md) · [Insiders](/companies/svra/insiders.md) Latest reported revenue: [$0](/filings/0000950170-21-004253.md) for Q3 FY2021, three months to 2021-09-30, from the 10-Q filed Nov 12, 2021 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0000950170-21-004253). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.11)](/filings/0001193125-25-277525.md) | not reported | [(0.12)](/filings/0001193125-26-219371.md) | [(0.14)](/filings/0001193125-26-344585.md) | [(0.14)](/filings/0001193125-25-277525.md) | not reported | [(0.15)](/filings/0001193125-26-219371.md) | [(0.16)](/filings/0001193125-26-344585.md) | | Free cash flow | $m | [(22.7) d](/filings/0001193125-25-277525.md) | [(23.3) d](/filings/0001193125-26-105076.md) | [(27.2)](/filings/0001193125-26-219371.md) | [(26.3) d](/filings/0001193125-26-344585.md) | [(22.5) d](/filings/0001193125-25-277525.md) | [(25.1) d](/filings/0001193125-26-105076.md) | [(33.1)](/filings/0001193125-26-219371.md) | [(30.0) d](/filings/0001193125-26-344585.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.32)](/filings/0000950170-23-010967.md) | [(0.25)](/filings/0000950170-24-027920.md) | [(0.33)](/filings/0000950170-25-045731.md) | [(0.48)](/filings/0001193125-26-105076.md) | [(0.53)](/filings/0001193125-26-105076.md) | | Free cash flow | $m | [(40.1)](/filings/0000950170-23-010967.md) | [(34.6)](/filings/0000950170-24-027920.md) | [(51.4)](/filings/0000950170-25-045731.md) | [(89.1)](/filings/0001193125-26-105076.md) | [(101)](/filings/0001193125-26-105076.md) | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/svra/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [NEA Management Company, LLC](/funds/1512848.md) | 2026-06-30 | $150.7m | 24,471,264 | | Unchanged | | [Bain Capital Life Sciences Investors, LLC](/funds/1703031.md) | 2026-06-30 | $108.4m | 17,600,621 | | Unchanged | | [Venrock Adviser, LLC](/funds/1615982.md) | 2026-06-30 | $90.8m | 14,745,943 | | Added +1,005,568 | | [DEERFIELD MANAGEMENT COMPANY, L.P.](/funds/1009258.md) | 2026-06-30 | $83.6m | 13,569,000 | | Unchanged | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $77.0m | 12,494,498 | | Added +1,203,313 | | [TCG Crossover Management, LLC](/funds/1839948.md) | 2026-06-30 | $76.2m | 12,362,205 | | Unchanged | | [Frazier Life Sciences Management, L.P.](/funds/1892134.md) | 2026-06-30 | $59.9m | 9,720,852 | | Unchanged | | [Polar Capital Holdings Plc](/funds/1837309.md) | 2026-06-30 | $58.8m | 9,541,786 | | Unchanged | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $48.9m | 7,932,545 | | Added +148,632 | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $43.0m | 6,976,810 | | Reduced −367,973 | ## Recent filings [All 1,037 filings](/companies/svra/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-08-11 | 16:05 ET | [10-Q](/filings/0001193125-26-344585.md) | Quarterly report, period 2026-06-30 | 0001193125-26-344585 | | 2026-06-08 | 16:15 ET | [8-K](/filings/0001193125-26-261770.md) | 5.02 Departure or appointment of officers or directors; 5.03 Amendment to articles or bylaws; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-261770 | | 2026-05-12 | 16:05 ET | [10-Q](/filings/0001193125-26-219371.md) | Quarterly report, period 2026-03-31 | 0001193125-26-219371 | | 2026-04-24 | 16:22 ET | [DEF 14A](/filings/0001193125-26-177353.md) | Proxy statement, period 2026-06-04 | 0001193125-26-177353 | | 2026-03-13 | 08:30 ET | [8-K](/filings/0001193125-26-105099.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-105099 | | 2026-03-13 | 08:10 ET | [10-K](/filings/0001193125-26-105076.md) | Annual report, period 2025-12-31 | 0001193125-26-105076 | | 2026-01-27 | 08:10 ET | [8-K](/filings/0001193125-26-023378.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001193125-26-023378 | | 2026-01-09 | 08:00 ET | [8-K](/filings/0001193125-26-008301.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001193125-26-008301 | | 2025-11-14 | 16:27 ET | [SCHEDULE 13D/A](/filings/0001072613-25-000852.md) | Ownership report, active investor, amended | 0001072613-25-000852 | | 2025-11-12 | 16:05 ET | [10-Q](/filings/0001193125-25-277525.md) | Quarterly report, period 2025-09-30 | 0001193125-25-277525 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-105076.md), filed Mar 13, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1160308 - Tickers: SVRA - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.